

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 144
NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

OMB APPROVAL
OMB Number: 3235-0101
Expires: December 31, 2009
Estimated average burden hours per response 2.00
SEC USE ONLY
DOCUMENT SEQUENCE NO.
CUSIP NUMBER
WORK LOCATION

ATTENTION: *Transmit for filing 3 copies of this form concurrently with either placing an order with a broker to execute sale or executing a sale directly with a market maker.*

1 (a) NAME OF ISSUER (Please type or print) Phathom Pharmaceuticals, Inc.		b) IRS IDENT. NO. 82-4151574	c) S.E.C. FILE NO. 001-39094		WORK LOCATION	
1 (d) ADDRESS OF ISSUER 100 Campus Drive, Suite 102		STREET Florham Park		CITY NJ	STATE 07932	ZIP CODE
				(e) TELEPHONE NO.		
				AREA CODE 877		NUMBER 742-8466
2 (a) NAME OF PERSON FOR WHOSE ACCOUNT THE SECURITIES ARE TO BE SOLD Takeda Pharmaceutical Company Limited		b) RELATIONSHIP TO ISSUER Affiliate		c) ADDRESS STREET 1-1, Nihonbashi-Honcho 2-Chome		CITY Chuo-ku, Tokyo
				STATE 103-8668		ZIP CODE Japan

INSTRUCTION: The person filing this notice should contact the issuer to obtain the I.R.S. Identification Number and the S.E.C. File Number.

3 (a) Title of the Class of Securities To Be Sold	(b) Name and Address of Each Broker Through Whom the Securities are to be Offered or Each Market Maker who is Acquiring the Securities	SEC USE ONLY	(c) Number of Shares or Other Units To Be Sold (See instr. 3(c))	(d) Aggregate Market Value (See instr. 3(d))	(e) Number of Shares or Other Units Outstanding (See instr. 3(e))	(f) Approximate Date of Sale (See instr. 3(f)) (MO. DAY YR.)	(g) Name of Each Securities Exchange (See instr. 3(g))
		Broker-Dealer File Number					
Common Stock	Nomura Securities International, Inc. 309 West 49th Street New York, NY 10019		882,240 (1)	\$30,401,990 (2)	31,329,613	(1)	Nasdaq Global Select Market

INSTRUCTIONS:

1. (a) Name of issuer
(b) Issuer's I.R.S. Identification Number
(c) Issuer's S.E.C. file number, if any
(d) Issuer's address, including zip code
(e) Issuer's telephone number, including area code
2. (a) Name of person for whose account the securities are to be sold
(b) Such person's relationship to the issuer (e.g., officer, director, 10% stockholder, or member of immediate family of any of the foregoing)
(c) Such person's address, including zip code
3. (a) Title of the class of securities to be sold
(b) Name and address of each broker through whom the securities are intended to be sold
(c) Number of shares or other units to be sold (if debt securities, give the aggregate face amount)
(d) Aggregate market value of the securities to be sold as of a specified date within 10 days prior to filing of this notice
(e) Number of shares or other units of the class outstanding, or if debt securities the face amount thereof outstanding, as shown by the most recent report or statement published by the issuer
(f) Approximate date on which the securities are to be sold
(g) Name of each securities exchange, if any, on which the securities are intended to be sold

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

TABLE I — SECURITIES TO BE SOLD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired (If gift, also give date donor acquired)	Amount of Securities Acquired	Date of Payment	Nature of Payment
Equity Shares	5/7/2019	(3)	Phathom Pharmaceuticals, Inc.	882,240 (4)	5/7/2019	(3)

INSTRUCTIONS:

If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

TABLE II — SECURITIES SOLD DURING THE PAST 3 MONTHS

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Takeda Pharmaceutical Company Limited 1-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8668, Japan	See Annex A	See Annex A	See Annex A	See Annex A

REMARKS: (1) These shares will be sold pursuant to a Form 10b5-1 plan adopted by Takeda Pharmaceutical Company Limited ("Takeda") on April 2, 2021 (the "Plan"), which was previously disclosed by Takeda in a Form 144 submitted to the SEC dated April 2, 2021.
(2) Estimated based on the fair market value at close on June 28, 2021 of \$34.46/share
(3) Received as partial consideration for the license of certain rights by Takeda to Issuer
(4) Reflects remaining balance of 1,084,000 equity shares of the Issuer that Takeda initially acquired on May 7, 2019 and not yet sold pursuant to the Plan.

INSTRUCTIONS:

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Securities Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

June 30, 2021

DATE OF NOTICE

April 2, 2021

DATE OF PLAN ADOPTION OR GIVING OF INSTRUCTION,
IF RELYING ON RULE 10B5-1

Amir Singh
 Amir Singh for Vice President and Treasurer of Takeda Pharmaceutical Company Limited
 (SIGNATURE)

The notice shall be signed by the person for whose account the securities are to be sold. At least one copy of the notice shall be manually signed. Any copies not manually signed shall bear typed or printed signatures.

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Annex A

Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Common Stock	5/3/2021	14,632	\$560,098.33
Common Stock	5/4/2021	19,360	\$697,776.99
Common Stock	5/5/2021	6,936	\$243,739.36
Common Stock	5/6/2021	202	\$7,073.01
Common Stock	5/7/2021	1,011	\$35,412.60
Common Stock	5/12/2021	11,776	\$417,413.27
Common Stock	5/13/2021	100	\$3,533.00
Common Stock	5/14/2021	100	\$3,500.00
Common Stock	5/20/2021	7,098	\$249,173.87
Common Stock	5/21/2021	11,648	\$416,312.33
Common Stock	5/24/2021	10,594	\$377,832.89
Common Stock	5/25/2021	10,947	\$396,105.15
Common Stock	5/26/2021	12,358	\$452,726.68
Common Stock	5/27/2021	8,453	\$313,968.93
Common Stock	5/28/2021	8,905	\$322,296.88
Common Stock	6/1/2021	11,211	\$401,154.24
Common Stock	6/2/2021	4,300	\$151,275.29
Common Stock	6/7/2021	2,264	\$79,352.97
Common Stock	6/8/2021	100	\$3,500.00
Common Stock	6/9/2021	1,191	\$42,022.53
Common Stock	6/10/2021	2,102	\$73,859.87
Common Stock	6/14/2021	2,826	\$99,071.93
Common Stock	6/17/2021	3,305	\$115,937.75
Common Stock	6/18/2021	5,398	\$189,609.61
Common Stock	6/21/2021	9,294	\$328,163.70
Common Stock	6/22/2021	100	\$3,500.00
Common Stock	6/23/2021	200	\$7,000.00
Common Stock	6/24/2021	10,848	\$381,214.99
Common Stock	6/25/2021	24,131	\$856,537.08
Common Stock	6/28/2021	370	\$12,978.01